Intarcia has raised $1.89 billion across multiple rounds, including a $525M Series J (Aug 03, 2017), an $8M Series J (Jan 17, 2018) and a $198M Series J. Founded in 1995, Intarcia developed an implantable osmotic pump that delivers therapeutic drugs subcutaneously over extended periods targeting diabetes and other chronic conditions. Investment supported clinical trials, device engineering, regulatory submissions and scale manufacturing.